Leerink Partners analyst Mani Foroohar has maintained their bullish stance on BBIO stock, giving a Buy rating on February 21.
Mani Foroohar’s rating is based on the strong initial performance of BridgeBio Pharma’s Attruby launch, which indicates robust end-market demand. The company’s focus on improving key metrics such as prescription fill rates, patient assistance program participation, and treatment compliance is expected to drive further growth in script volume. Additionally, the company’s efforts to educate patients on the Medicare Prescription Payment Plan could enhance patient retention by mitigating the impact of out-of-pocket costs.
Foroohar’s updated financial model reflects higher-than-expected script volumes and conservative assumptions that still project significant sales growth for FY25. Despite potential competition from ALNY’s vutrisiran, the model anticipates a strong market share for Attruby, supported by favorable industry metrics. The analysis suggests that BridgeBio Pharma’s performance could exceed consensus expectations, reinforcing the Buy rating with a price target of $48.
In another report released on February 21, Scotiabank also maintained a Buy rating on the stock with a $52.00 price target.